DK0707644T3 - Anvendelse af farmaceutiske præparater til behandling af neurodegenerative sygdomme - Google Patents
Anvendelse af farmaceutiske præparater til behandling af neurodegenerative sygdommeInfo
- Publication number
- DK0707644T3 DK0707644T3 DK94920987T DK94920987T DK0707644T3 DK 0707644 T3 DK0707644 T3 DK 0707644T3 DK 94920987 T DK94920987 T DK 94920987T DK 94920987 T DK94920987 T DK 94920987T DK 0707644 T3 DK0707644 T3 DK 0707644T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- pharmaceutical compositions
- neurodegenerative diseases
- new
- interaction
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108091023040 Transcription factor Proteins 0.000 abstract 3
- 102000040945 Transcription factor Human genes 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 102000007999 Nuclear Proteins Human genes 0.000 abstract 1
- 108010089610 Nuclear Proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307962A FR2707880B1 (fr) | 1993-06-30 | 1993-06-30 | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives. |
| PCT/FR1994/000771 WO1995001429A1 (fr) | 1993-06-30 | 1994-06-27 | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0707644T3 true DK0707644T3 (da) | 2005-01-17 |
Family
ID=9448720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94920987T DK0707644T3 (da) | 1993-06-30 | 1994-06-27 | Anvendelse af farmaceutiske præparater til behandling af neurodegenerative sygdomme |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6140112A (sv) |
| EP (2) | EP0707644B1 (sv) |
| JP (1) | JP3755825B2 (sv) |
| KR (1) | KR100517879B1 (sv) |
| AT (1) | ATE276360T1 (sv) |
| AU (1) | AU696644B2 (sv) |
| CA (1) | CA2166318C (sv) |
| DE (1) | DE69433996T2 (sv) |
| DK (1) | DK0707644T3 (sv) |
| ES (1) | ES2227528T3 (sv) |
| FI (1) | FI120942B (sv) |
| FR (1) | FR2707880B1 (sv) |
| NO (1) | NO321455B1 (sv) |
| PT (1) | PT707644E (sv) |
| WO (1) | WO1995001429A1 (sv) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| KR20000036227A (ko) | 1996-09-27 | 2000-06-26 | 토마스 씨. 서 | 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법 |
| DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
| US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
| CN1315402A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸 |
| CN1315439A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸 |
| DE10308045B3 (de) | 2003-02-26 | 2004-06-17 | Lurgi Ag | Verfahren und Vorrichtung zur kontinuierlichen Gewinnung freier Weinsäure aus Kaliumhydrogentartrat enthaltenden Rohstoffen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| WO1991011535A1 (en) * | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
| AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| GB9114437D0 (en) * | 1991-07-03 | 1991-08-21 | Health Lab Service Board | Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes |
| FR2708283B1 (fr) * | 1994-01-14 | 1995-10-20 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives. |
-
1993
- 1993-06-30 FR FR9307962A patent/FR2707880B1/fr not_active Expired - Lifetime
-
1994
- 1994-06-27 DK DK94920987T patent/DK0707644T3/da active
- 1994-06-27 EP EP94920987A patent/EP0707644B1/fr not_active Expired - Lifetime
- 1994-06-27 ES ES94920987T patent/ES2227528T3/es not_active Expired - Lifetime
- 1994-06-27 PT PT94920987T patent/PT707644E/pt unknown
- 1994-06-27 CA CA002166318A patent/CA2166318C/fr not_active Expired - Lifetime
- 1994-06-27 EP EP04006618A patent/EP1454984A1/fr not_active Withdrawn
- 1994-06-27 AT AT94920987T patent/ATE276360T1/de active
- 1994-06-27 KR KR1019950706050A patent/KR100517879B1/ko not_active Expired - Lifetime
- 1994-06-27 JP JP50330895A patent/JP3755825B2/ja not_active Expired - Lifetime
- 1994-06-27 US US08/569,149 patent/US6140112A/en not_active Expired - Lifetime
- 1994-06-27 AU AU71882/94A patent/AU696644B2/en not_active Expired
- 1994-06-27 WO PCT/FR1994/000771 patent/WO1995001429A1/fr active IP Right Grant
- 1994-06-27 DE DE69433996T patent/DE69433996T2/de not_active Expired - Lifetime
-
1995
- 1995-12-01 NO NO19954888A patent/NO321455B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956353A patent/FI120942B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI120942B (sv) | 2010-05-14 |
| WO1995001429A1 (fr) | 1995-01-12 |
| AU696644B2 (en) | 1998-09-17 |
| JPH08512043A (ja) | 1996-12-17 |
| NO954888D0 (no) | 1995-12-01 |
| AU7188294A (en) | 1995-01-24 |
| EP0707644B1 (fr) | 2004-09-15 |
| ATE276360T1 (de) | 2004-10-15 |
| KR100517879B1 (ko) | 2005-12-16 |
| FR2707880A1 (fr) | 1995-01-27 |
| FI956353A0 (sv) | 1995-12-29 |
| PT707644E (pt) | 2005-01-31 |
| KR960703432A (ko) | 1996-08-17 |
| CA2166318C (fr) | 2009-02-10 |
| ES2227528T3 (es) | 2005-04-01 |
| JP3755825B2 (ja) | 2006-03-15 |
| NO321455B1 (no) | 2006-05-15 |
| EP0707644A1 (fr) | 1996-04-24 |
| DE69433996T2 (de) | 2005-09-22 |
| FR2707880B1 (fr) | 1995-10-06 |
| NO954888L (no) | 1995-12-01 |
| US6140112A (en) | 2000-10-31 |
| DE69433996D1 (de) | 2004-10-21 |
| CA2166318A1 (fr) | 1995-01-12 |
| EP1454984A1 (fr) | 2004-09-08 |
| FI956353L (sv) | 1995-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434820D1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
| EP1005376A4 (en) | METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA | |
| DE69233760D1 (de) | Inhibitoren der menschlichen Elastase von Neutrophilen | |
| BR9507506A (pt) | Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| DK1003546T3 (da) | Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon | |
| DE69634698D1 (de) | Gewebespezifische und ziel-rna-spezifische ribozyme | |
| DK0707644T3 (da) | Anvendelse af farmaceutiske præparater til behandling af neurodegenerative sygdomme | |
| FI880961A7 (sv) | Synergistisk effekt av lymfokiner och dubbelsträngade RNA-sekvenser. | |
| ATE99953T1 (de) | Antivirales kombinationspraeparat. | |
| HK1044896A1 (zh) | 治療hiv感染和與之有關的繼發感染的方法 | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| BR9306207A (pt) | Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo | |
| NO945031L (no) | Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner | |
| FR2701960B1 (fr) | Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme. | |
| ATE311446T1 (de) | Pharmazeutische zusammensetzungen und deren verwendung insbesondere in der behandlung von neurodegenerativen krankheiten | |
| FI950649A7 (sv) | Substituerade cyklohexanolestrar, användning av dessa för behandling av sjukdomar och farmaceutiska preparat | |
| EP1143981A4 (en) | TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS | |
| MXPA94003453A (es) | Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica. | |
| LTIP1943A (en) | Arylating agents, used in the treatment of cancerand disease caused by viral infection | |
| ATE332704T1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
| ATE65543T1 (de) | Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. |